Transgene Reports Positive Data on its Tasly-Partnered HBV Therapy

Transgene reported its therapeutic hepatitis B vaccine was safe and promoted immunogenicity in a Phase I/Ib trial. A JV formed by France 's Transgene and China 's Tasly Pharma has filed for CFDA approval to begin clinical trials of TG1050 in China . With a single dose, TG1050 provoked a specific immune response in the first cohort of patients treated. The TG1050 immunotherapy was administered as an addition to a standard antiviral regimen, which can take as long as 15 years to cure hepatitis B. More details.... Stock Symbols: (Euronext: TNG) (SHA: 600535) Share this with colleagues: // //